The α 1B/D-adrenoceptor knockout mouse permits isolation of the vascular α 1A-adrenoceptor and elucidates its relationship to the other subtypes

British Journal of Pharmacology

Volumn 158, Issue 1, 2009, Pages 209-224

  Methven, L ^a   McBride, M ^a   Wallace, Ga ^a   McGrath, Jc ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

1B D adrenoceptor knockout; Adrenoceptor; Confocal microscopy; Fluorescent ligand binding; Vascular smooth muscle; Wire myography

Indexed keywords

5 METHYL 3 [3 [4 [2 (2,2,2 TRIFLUOROETHOXY)PHENYL] 1 PIPERAZINYL]PROPYL] 1H PYRIMIDINE 2,4 DIONE; 5 METHYLURAPIDIL; 8 [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] 8 AZASPIRO[4.5]DECANE 7,9 DIONE; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1B ADRENERGIC RECEPTOR; ALPHA 1D ADRENERGIC RECEPTOR; N [(2 TRIFLUOROETHOXY)PHENYL] N' (3 THYMINYLPROPYL)PIPERAZINE; PIPERAZINE DERIVATIVE; PRAZOSIN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CAROTID ARTERY; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG RECEPTOR BINDING; KNOCKOUT MOUSE; LIGAND BINDING; MALE; MOUSE; MYOGRAPHY; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION; WILD TYPE;

ADRENERGIC AGONISTS; ADRENERGIC ANTAGONISTS; ANIMALS; CAROTID ARTERIES; MALE; MESENTERIC ARTERIES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; PROTEIN SUBUNITS; RECEPTORS, ADRENERGIC, ALPHA-1;

EID: 69249211015     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00269.x     Document Type: Article

References (53)

1. Alexander SPH, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC). Br J Pharmacol 153 : S14.
2. Buckner SA, Oheim KW, Morse PA, Knepper SM, Hancock AA (1996). Adrenoceptor-induced contractility in rat aorta is mediated by the alpha (1D) subtype. Eur J Pharmacol 297 : 241 248.
3. Castillo EF, López RM, Rodríguez-Silverio J, Bobadilla RA, Castillo C (1998). Alpha 1D-adrenoceptors contribute to the neurogenic vasopressor response in pithed rats. Fundam Clin Pharmacol 12 : 584 589. (Pubitemid 29535480)
4. Cavalli A, Lattion AL, Hummler E, Nenniger M, Pedrazzini T, Aubert JF et al. (1997). Decreased blood pressure response in mice deficient of the alpha 1b-adrenergicreceptor. Proc Natl Acad Sci 94 : 11589 11594.
5. Daly CJ, McGrath I (2003). Fluorescent ligands, antibodies, and proteins for the study of receptors. Pharmacol Ther 100 : 101 118.
6. Daly CJ, Milligan CM, Milligan G, Mackenzie JF, McGrath JC (1998). Cellular localization and pharmacological characterization of functioning alpha-1 adrenoceptors by fluorescent ligand binding and image analysis reveals identical binding properties of clustered and diffuse populations. of receptors. J Pharmacol Exp Ther 286 : 984 990.
7. 1B-adrenoceptors in mouse. Physiol Genomics 9 : 85 91.
8. 1B-adrenoceptor knockout mice reveal compensatory adrenoceptor subtype substitution. Br J Pharmacol 142 : 1031 1037.
9. 1-adrenoceptor subtypes in mouse carotid arteries using knockout mice. Br J Pharmacol 144 : 558 565.
10. Flavahan NA, Vanhoutte PM (1986). [alpha]1-adrenoceptor subclassification in vascular smooth muscle. Trends Pharmacol Sci 7 : 347 349.
11. Garcia-Sainz JA, Romero-Avila M, Torres-Marquez ME (1995). Characterization of the human liver alpha 1-adrenoceptors: predominance of the alpha 1A subtype. Eur J Pharmacol 289 : 81 86.
12. Goetz AS, Lutz MW, Rimele TJ, Saussy DLJ (1994). Characterisation of alpha-1-adrenoceptor subtypes in human and canine prostate membrane. J Pharmacol Exp Ther 271 : 1228 1233.
13. Goetz AS, King HK, Ward SDC, True TA, Rimele TJ, Saussy J (1995). BMY 7378 is a selective antagonist of the D subtype of [alpha]1-adrenoceptors. Eur J Pharmacol 272 : R5 R6.
14. Gross G, Hanft G, Rugevics C (1988). 5-Methyl-urapidil discriminates between subtypes of the [alpha]1-adrenoceptor. Eur J Pharmacol 151 : 333 335.
15. Guimaraes S, Moura D (2001). Vascular adrenoceptors: an update. Pharmacol Rev 53 : 319 356.
16. Hague C, Chen Z, Pupo AS, Schulte NA, Toews ML, Minneman KP (2004a). The N terminus of the human alpha1D-adrenergic receptor prevents cell surface expression. J Pharmacol Exp Ther 309 : 388 397.
17. Hague C, Uberti M, Chen Z, Hall R, Minneman KP (2004b). Cell surface expressin of alpha 1D-adrenergic receptors is controlled by heterodimerization with alpha 1B-adrenergic receptors. J Biol Chem 279 (15 15541 15549.
18. Hieble JP, Bylund DB, Clarke DE, Eikenburg DC, Langer SZ, Lefkowitz RJ et al. (1995). International Union of Pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: consensus update. Pharmacol Rev 47 : 267 270.
19. Hirasawa A, Sugawara T, Awaji T, Tsumaya K, Ito H, Tsujimoto G (1997). Subtype-specific differences in subcellular localization of alpha 1-adrenoceptors: chlorethylclonidine preferentially alkylates the accessible cell surface alpha 1-adrenoceptors irrespective of the subtype. Mol Pharmacol 52 : 764 770.
20. Hosoda C, Koshimizu TA, Tanoue A, Nasa Y, Oikawa R, Tomabechi T et al. (2005). Two alpha1-adrenergic receptor subtypes regulating the vasopressor response have differential roles in blood pressure regulation. Mol Pharmacol 67 : 912 922.
21. Hrometz SL, Edelmann SE, McCune DF, Olges JR, Hadley RW, Perez DM et al. (1999). Expression of multiple alpha 1-adrenoceptors on vascular smooth muscle: correlation with the regulation of Contraction. J Pharmacol Exp Ther 290 : 452 463.
22. 1D-adrenoceptor mediating the contractile response of rat aorta to noradrenaline. Br J Pharmacol 115 : 981 986.
23. Knepper SM, Buckner SA, Brune ME, DeBernardis JF, Meyer MD, Hancock AA (1995). A-61603, a potent alpha 1-adrenergic receptor agonist, selective for the alpha 1A receptor subtype. J Pharmacol Exp Ther 274 : 97 103.
24. Leonardi A, Heible JP, Guarneri L, Naselsky DP, Poggesi E, Sironi G et al. (1997). Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): role of the alpha-1L adrenoceptor in tissue selectivity, part I. J Pharmacol Exp Ther 281 : 1272 1283.
25. McCune DF, Edelmann SE, Olges JR, Post GR, Waldrop BA, Waugh DJJ et al. (2000). Regulation of the cellular localization and signaling properties of the alpha 1B- and alpha 1D-adrenoceptors by agonists and inverse agonists. Mol Pharmacol 57 : 659 666.
26. McGrath I, Deighan C, Briones A, Malekzadeh-Shafaroudi M, McBride M, Adler J et al. (2005). New aspects of vascular remodelling: the involvement of all vascular cell types. Exp Physiol 90 : 469 475.
27. Mackenzie JF, Daly CJ, Pediani JD, McGrath JC (2000). Quantitative imaging in live human cells reveals intracellular alpha 1-adrenoceptor ligand-binding sites. J Pharmacol Exp Ther 294 : 434 443.
28. Martinez-Salas SG, Campos-Peralta JM, Pares-Hipolito J, Gallardo-Ortiz IA, Ibarra M, Villalobos-Molina R (2007). Alpha-1A adrenoceptors predominate in the control of blood pressure in mouse mesenteric vascular bed. Auton Autacoid Pharmacol 27 : 137 142.
29. Meyer MD, Altenbach RJ, Hancock AA, Buckner SA, Knepper SM, Kerwin JF (1996). Synthesis and in vitro characterization of N-[5-(4,5-dihydro-1H- imidazol-2-yl)-2-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]methanesulfonamide and its enantiomers: a novel selective alpha-1a receptor agonist. J Med Chem 39 : 4116 4119.
30. Michel MC, Goepel M (1998). Differential alpha-1 adrenoceptor labeling by [3H]-prazosin and [3H]-tamsulosin. Eur J Pharmacol 342 : 85 92.
31. Miquel RM, Segura V, Ali Z, D'Ocon P, McGrath JC, Daly CJ (2005). 3-D image analysis of fluorescent drug binding. Mol Imaging 4 : 1 13.
32. Morris DP, Price RR, Smith MP, Lei B, Schwinn DA (2004). Cellular trafficking of human {alpha}1a-adrenergic receptors is continuous and primarily agonist-independent. Mol Pharmacol 66 : 843 854.
33. 1-adrenoceptors in vascular smooth muscle. Br J Pharmacol 99 : 197 201.
34. 1A-adrenoceptor gene knockout. Br J Pharmacol 155 : 1224 1234.
35. Pediani J, Mackenzie JF, Heeley RP, Daly CJ, McGrath JC (2000). Single-cell recombinant pharmacology: bovine alpha-1a adrenoceptors in rat-1 fibroblasts release intracellular calcium, display subtype-characteristic agonism and antagonism and exhibit an antagonist-reversible inverse concentration-response phase. J Pharmacol Exp Ther 293 : 895.
36. Pediani JD, Colston JF, Caldwell D, Milligan G, Daly CJ, McGrath JC (2005). Beta-arrestin-dependent spontaneous alpha-1a-adrenoceptor endocytosis causes intracellular transportation of alpha-blockers via recycling compartments. Mol Pharmacol 67 : 1004.
37. Peng H, Matchkov V, Ivarsen A, Aalkjar C, Nilsson H (2001). Hypothesis for the initiation of vasomotion. Circ Res 88 : 810 815.
38. Piascik MT, Hrometz SL, Edelmann SE, Guarino RD, Hadley RW, Brown RD (1997). Immunocytochemical localization of the alpha-1B adrenergic receptor and the contribution of this and the other subtypes to vascular smooth muscle contraction: analysis with selective ligands and antisense oligonucleotides. J Pharmacol Exp Ther 283 : 854 868.
39. Rokosh DG, Simpson PC (2002). Knockout of the alpha 1A/C-adrenergic receptor subtype: the alpha 1A/C is expressed in resistance arteries and is required to maintain arterial blood pressure. Proc Natl Acad Sci 99 : 9474 9479.
40. Saussy DJ, Goetz AS, Queen KL, King HK, Lutz MW, Rimele TJ (1996). Structure activity relationships of a series of buspirone analogs at alpha-1 adrenoceptors: further evidence that rat aorta alpha-1 adrenoceptors are of the alpha-1D-subtype. J Pharmacol Exp Ther 278 : 136 144.
41. Stanasila L, Perez JB, Vogel H, Cotecchia S (2003). Oligomerization of the {alpha}1a- and {alpha}1b-adrenergic receptor subtypes: potential implications in receptor internalization. J Biol Chem 278 : 40239 40251.
42. Sugawara T, Hirasawa A, Hashimoto K, Tsujimoto G (2002). Differences in the subcellular localization of α1-adrenoceptor subtypes can affect the subtype selectivity of drugs in a study with the fluorescent ligand BODIPY FL-prazosin. Life Sci 70 : 2113 2124.
43. Tanoue A, Koba M, Miyawaki S, Koshimizu TA, Hosoda C, Oshikawa S et al. (2002a). Role of the {alpha}1D-adrenegric receptor in the development of salt-induced hypertension. Hypertension 40 : 101 106.
44. Tanoue A, Nasa Y, Koshimizu T, Shinoura H, Oshikawa S, Kawai T et al. (2002b). The {alpha}1D-adrenergic receptor directly regulates arterial blood pressure via vasoconstriction. J Clin Invest 109 : 765 775.
45. Testa R, Guarneri L, Angelico P, Poggesi E, Taddei C, Sironi G et al. (1997). Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): role of the alpha-1L adrenoceptor in tissue selectivity, part II. J Pharmacol Exp Ther 281 : 1284 1293.
46. Turnbull L, McCloskey DT, O'Connell TD, Simpson PC, Baker AJ (2003). Alpha 1-adrenergic receptor responses in alpha 1AB-AR knockout mouse hearts suggest the presence of alpha 1D-AR. Am J Physiol Heart Circ Physiol 284 : H1104 H1109.
47. Uberti M, Hall R, Minneman KP (2003). Subtype-specific dimerization of alpha1-adrenoceptors: effects on receptor expression and pharmacological properties. Mol Pharmacol 64 : 1379 1390.
48. Villalobos-Molina R, Ibarra M (1996). [alpha]1-Adrenoceptors mediating contraction in arteries of normotensive and spontaneously hypertensive rats are of the [alpha]1D or [alpha]1A subtypes. Eur J Pharmacol 298 : 257 263.
49. 1A-adrenoceptor selective antagonists. Br J Pharmacol 127 : 252 258.
50. Yoshio R, Taniguchi T, Itoh H, Muramatsu I (2001). Affinity of serotonin receptor antagonists and agonists to recombinant and native alpha1-adrenoceptor subtypes. Jpn J Pharmacol 86 : 189 195.
51. 1-Adrenoceptor subtypes involved in vasoconstrictor responses to exogenous and neurally released noradrenaline in rat femoral resistance arteries. Br J Pharmacol 141 : 915 924.
52. 1D-adrenoceptors in contraction of femoral resistance arteries using knockout mice. Br J Pharmacol 146 : 942 951.
53. Zhou l, Vargas HM (1996). Vascular alpha 1D-adrenoceptors have a role in the pressor response to phenylephrine in the pithed rat. Eur J Pharmacol 305 : 173 176.